Arrowstreet Capital
ENTA icon

Arrowstreet Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Arrowstreet Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-52,728
Closed -$832K – 1917
2025
Q4 		$832K Buy
+52,728
New +$670K ﹤0.01% 1592
2022
Q1 		– Sell
-41,642
Closed -$3.11M – 1290
2021
Q4 		$3.11M Buy
+41,642
New +$3.27M ﹤0.01% 925
2021
Q2 		– Sell
-8,400
Closed -$414K – 1971
2021
Q1 		$414K Sell
8,400
-8,831
-51% -$440K ﹤0.01% 2043
2020
Q4 		$725K Buy
17,231
+12,231
+245% +$538K ﹤0.01% 1915
2020
Q3 		$229K Buy
+5,000
New +$242K ﹤0.01% 2180
2020
Q1 		– Sell
-8,000
Closed -$494K – 1931
2019
Q4 		$494K Buy
+8,000
New +$496K ﹤0.01% 1491
2019
Q1 		– Sell
-6,800
Closed -$482K – 1772
2018
Q4 		$482K Buy
+6,800
New +$521K ﹤0.01% 1096
2018
Q2 		– Sell
-50,694
Closed -$4.1M – 1136
2018
Q1 		$4.1M Buy
50,694
+30,404
+150% +$2.34M 0.01% 614
2017
Q4 		$1.19M Buy
+20,290
New +$1.02M ﹤0.01% 929
2016
Q4 		– Sell
-16,600
Closed -$442K – 1883
2016
Q3 		$442K Buy
+16,600
New +$386K ﹤0.01% 1279
2014
Q4 		– Sell
-15,322
Closed -$606K – 1255
2014
Q3 		$606K Sell
15,322
-25,675
-63% -$1.02M ﹤0.01% 803
2014
Q2 		$1.77M Sell
40,997
-18,710
-31% -$714K 0.01% 620
2014
Q1 		$2.39M Buy
+59,707
New +$2.17M 0.01% 617

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital's ENTA Position: Q1 2026 in Review

Arrowstreet Capital sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 52,728 shares — an estimated $832K sold.

Arrowstreet Capital first reported a position in ENTA in Q1 2014 and held it in 13 quarters. The position peaked at $4.1M in Q1 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Arrowstreet Capital reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 52,728 Enanta Pharmaceuticals shares in Q1 2026, an estimated $832K.
  • Arrowstreet Capital first reported a position in Enanta Pharmaceuticals in Q1 2014 and held it in 13 quarters.
  • Arrowstreet Capital's Enanta Pharmaceuticals position peaked at $4.1M in Q1 2018.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.